Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Pharmaxis receives approval to market Bronchitol in the EU

Pharmaxis is pleased to announce it has received Marketing Authorisation for Bronchitol from the European Commission.

Bronchitol to be reimbursed in Australia

Bronchitol has been recommended for listing on the Pharmaceutical Benefits Scheme for the treatment of cystic fibrosis.

Results of entitlement offer

On 16 November 2011, Pharmaxis announced an Etitlement Offer to raise approximately $80 million, comprising an institutional component and a retail component. This Entitlement Offer is now fully underwritten.

Pharmaxis announces agreement for European supply of Bronchitol

Pharmaxis has finalised a logistics and distribution services agreement for the supply of Bronchitol across Europe.